Solomon Daniel H, Rassen Jeremy A, Glynn Robert J, Lee Joy, Levin Raisa, Schneeweiss Sebastian
Division of Pharmacoepidemiology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Arch Intern Med. 2010 Dec 13;170(22):1968-76. doi: 10.1001/archinternmed.2010.391.
The safety of alternative analgesics is unclear. We examined the comparative safety of nonselective NSAIDs (nsNSAIDs), selective cyclooxygenase 2 inhibitors (coxibs), and opioids.
Medicare beneficiaries from Pennsylvania and New Jersey who initiated therapy with an nsNSAID, a coxib, or an opioid from January 1, 1999, through December 31, 2005, were matched on propensity scores. We studied the risk of adverse events related to analgesics using incidence rates and adjusted hazard ratios (HRs) from Cox proportional hazards regression.
The mean age of participants was 80.0 years, and almost 85% were female. After propensity score matching, the 3 analgesic cohorts were well balanced on baseline covariates. Compared with nsNSAIDs, coxibs (HR, 1.28; 95% confidence interval [CI], 1.01-1.62) and opioids (1.77; 1.39-2.24) exhibited elevated relative risk for cardiovascular events. Gastrointestinal tract bleeding risk was reduced for coxib users (HR, 0.60; 95% CI, 0.35-1.00) but was similar for opioid users. Use of coxibs and nsNSAIDs resulted in a similar risk for fracture; however, fracture risk was elevated with opioid use (HR, 4.47; 95% CI, 3.12-6.41). Use of opioids (HR, 1.68; 95% CI, 1.37-2.07) but not coxibs was associated with an increased risk for safety events requiring hospitalization compared with use of nsNSAIDs. In addition, use of opioids (HR, 1.87; 95 CI, 1.39-2.53) but not coxibs raised the risk of all-cause mortality compared with use of nsNSAIDs.
The comparative safety of analgesics varies depending on the safety event studied. Opioid use exhibits an increased relative risk of many safety events compared with nsNSAIDs.
非传统镇痛药的安全性尚不清楚。我们研究了非选择性非甾体抗炎药(nsNSAIDs)、选择性环氧化酶2抑制剂(coxibs)和阿片类药物的相对安全性。
对1999年1月1日至2005年12月31日期间在宾夕法尼亚州和新泽西州开始使用nsNSAIDs、coxibs或阿片类药物进行治疗的医疗保险受益人,根据倾向得分进行匹配。我们使用Cox比例风险回归的发病率和调整后的风险比(HRs)研究了与镇痛药相关的不良事件风险。
参与者的平均年龄为80.0岁,近85%为女性。在倾向得分匹配后,三个镇痛药队列在基线协变量上具有良好的平衡性。与nsNSAIDs相比,coxibs(HR,1.28;95%置信区间[CI],1.01 - 1.62)和阿片类药物(1.77;1.39 - 2.24)在心血管事件方面表现出相对风险升高。Coxib使用者的胃肠道出血风险降低(HR,0.60;95% CI,0.35 - 1.00),但阿片类药物使用者的胃肠道出血风险与之相似。使用coxibs和nsNSAIDs导致骨折的风险相似;然而,使用阿片类药物会增加骨折风险(HR,4.47;95% CI,3.12 - 6.41)。与使用nsNSAIDs相比,使用阿片类药物(HR,1.68;95% CI,1.37 - 2.07)而非coxibs与需要住院治疗的安全事件风险增加相关。此外,与使用nsNSAIDs相比,使用阿片类药物(HR,1.87;95 CI,1.39 - 2.53)而非coxibs会增加全因死亡率的风险。
镇痛药的相对安全性因所研究的安全事件而异。与nsNSAIDs相比,使用阿片类药物在许多安全事件中表现出相对风险增加。